A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
調査の概要
詳細な説明
Cetuximab is an immunoglobulin G1 (IgG1) monoclonal antibody that enhances the effects of some common chemotherapy agents and radiotherapy and demonstrates minimal overlapping toxicities with these approaches. This prospective, observational, non-interventional and multi-centric post marketing surveillance study is being conducted to collect safety information from subjects with locally advanced or recurrent/metastatic SCCHN treated with cetuximab based on the locally approved label. Study plans to enroll 200 to 300 subjects, who are eligible for cetuximab treatment according to the indication in the approved label of cetuximab by Taiwan Health Authority. Data related to subjects' demographics, relevant tumor history, and laboratory information (hematology, biochemistry) will be captured and analyzed descriptively.
OBJECTIVES
Primary objective:
• To obtain safety information on the use of cetuximab in subjects with SCCHN according to the regulatory approved label and in a regular clinical setting
Secondary objectives:
• To gather clinical efficacy information of the treatment
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Tainan County
-
Liouying、Tainan County、台湾
- Liouying Chi-Mei Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Histologically proven Stage 3-4 locally advanced SCCHN (oropharynx, hypopharynx, larynx) or recurrent and/or metastatic SCCHN
- Age greater than or equal to 18 years
- Signed informed consent
Exclusion Criteria:
- Subjects with known severe (Grade 3 or 4; National Cancer Institute Common Toxicity Criteria Version 4.03) hypersensitivity reactions to Cetuximab
- Subjects with contraindications for concomitantly used chemotherapeutic agents or radiation therapy, identified before initiation of cetuximab combination treatment
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
---|---|
非介入研究
|
Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m^2 for 60 minutes infusion period, will be observed.
The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Number of adverse drug reactions and serious adverse drug reactions
時間枠:From the first infusion of cetuximab until three months after the last infusion of Cetuximab
|
From the first infusion of cetuximab until three months after the last infusion of Cetuximab
|
Number of subjects discontinuing the study due to intolerability of cetuximab
時間枠:From the first infusion of cetuximab until three months after the last infusion of Cetuximab
|
From the first infusion of cetuximab until three months after the last infusion of Cetuximab
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Number of subjects with best tumor response categories that are, complete response, partial response, stable disease, progressive disease and not evaluable
時間枠:From the first infusion of cetuximab until three months after the last infusion of cetuximab
|
From the first infusion of cetuximab until three months after the last infusion of cetuximab
|
Time to progression
時間枠:From the first infusion of cetuximab until three months after the last infusion of cetuximab
|
From the first infusion of cetuximab until three months after the last infusion of cetuximab
|
Duration of response
時間枠:From the first infusion of cetuximab until three months after the last infusion of cetuximab
|
From the first infusion of cetuximab until three months after the last infusion of cetuximab
|
Overall Survival
時間枠:From the first infusion of cetuximab to death until three months after the last infusion of cetuximab
|
From the first infusion of cetuximab to death until three months after the last infusion of cetuximab
|
協力者と研究者
捜査官
- 主任研究者:Chao-Jung Tsao, Dr.、Liouying Chi-Mei Hospital
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
No Interventionの臨床試験
-
University of California, San FranciscoSan Francisco Veterans Affairs Medical Center; Tobacco Related Disease Research Program完了
-
University of MichiganNational Institute on Drug Abuse (NIDA)積極的、募集していない
-
University of Southern CaliforniaNational Institutes of Health (NIH)積極的、募集していない
-
University of PittsburghCenters for Disease Control and Prevention募集暴力, ドメスティック | 思春期の暴力 | 暴力、性的 | 暴力、身体的 | 暴力, 偶然ではない | 社会的結束 | 暴力、構造 | コミュニティ内暴力アメリカ
-
Munich Municipal HospitalTechnical University of Munich; University of Regensburgわからない
-
Massachusetts General HospitalNational Institutes of Health (NIH); Samaritans of Bostonまだ募集していません自殺念慮 | 自殺未遂 | 自殺